Next Article in Journal
Dry Carbonate Sorbents for CO2 Capture from Flue Gases: Role of Support in Adsorption Efficiency and Thermal Stability
Previous Article in Journal
Design and Synthesis of Sulfonium and Selenonium Derivatives Bearing 3′,5′-O-Benzylidene Acetal Side Chain Structure as Potent α-Glucosidase Inhibitors
Previous Article in Special Issue
An Investigation into the Interaction between Double Hydroxide-Based Antioxidant Benzophenone Derivatives and Cyclooxygenase 2
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 30
Issue 13
10.3390/molecules30132857
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

One-Pot Synthesis of Novel Pyrimidine Derivatives with Potential Antidiabetic Activity Through Dual α-Glucosidase and α-Amylase Inhibitors

by
Ohood Al-Shehri
1,2,
Samar Abubshait
1,2,*,
Muhammad Nawaz
3,
Mohamed S. Gomaa
4 and
Haya A. Abubshait
5
1
Department of Chemistry, College of Science, Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia
2
Basic and Applied Scientific Research Center, Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia
3
Department of Nano-Medicine Research, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia
4
Department of Pharmaceutical Chemistry, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia
5
Basic Sciences Department, Deanship of Preparatory Year and Supporting Studies, Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia
*
Author to whom correspondence should be addressed.
Molecules 2025, 30(13), 2857; https://doi.org/10.3390/molecules30132857
Submission received: 26 May 2025 / Revised: 29 June 2025 / Accepted: 30 June 2025 / Published: 4 July 2025
(This article belongs to the Special Issue Molecular Docking in Drug Discovery, 2nd Edition)
Browse Figures
Versions Notes

Abstract

This study describes the synthesis of heterocyclic derivatives containing multiple nitrogen atoms serving as important moieties for developing novel antidiabetics through a simple synthetic pathway. We herein describe the synthesis and characterization of novel pyrimidine derivatives using one-pot reactions in a catalyst-free and efficient manner through a two-stage process involving the synthesis of 2-amino-4-hydrazinyl-6-methoxy pyrimidine, followed by a reaction with phenyl isothiocyanate derivatives. The structures of all the new compounds were confirmed via physical and spectral analysis. Furthermore, we evaluated the synthesized pyrimidine derivatives’ biological activities in relation to their potential roles as novel anti-diabetic agents by testing their activity profiles against the enzymes α-glucosidase and α-amylase. Compound 4 expressed the highest level of activity against α-glucosidase and α-amylase, with a greater inhibitory concentration (IC50 of 12.16 ± 0.12 µM and IC50 11.13 ± 0.12 µM) compared to that of acarbose (IC50 = 10.60 ± 0.17 µM and IC50 = 11.30 ± 0.12 µM), which is widely used as a standard antidiabetic drug. The primary structure activity relationship analysis identified the impact of an electron- withdrawing group, especially with respect to fluorine on inhibitory activity. This was further confirmed in molecular docking studies, which demonstrated that both compounds exhibited similar inhibition patterns and emphasized the significance of incorporating a lipophilic electron-withdrawing substituent on the phenyl ring, along with the 2,4-diaminopyrimidine scaffold.

1. Introduction

Because of their vast range of applications, heterocyclic compounds have been the subject of a great deal of research in the last ten years. Pyridazine, pyrimidine, and pyrazine are examples of heterocyclic compounds that have a six-membered ring with two nitrogen atoms, known as diazines. These derivatives play a significant role in biological, pharmacological, industrial, and medical processes [1]. The derivatives of pyrimidine, which are especially important in biological systems, include nucleic acids [2]. The pyrimidine moiety is a crucial building block found in many different pharmaceutical types. Since it is an essential component of DNA and RNA, pyrimidine has been extracted from hydrolyzed nucleic acids and offers a variety of pharmacological characteristics [3,4,5]. Although pyrimidine derivatives have been described as having broad biological potential, most published research reports concentrate on pharmacological properties, such as their antimicrobial [6], antifungal [7,8], antivirus [9,10], anticancer [11,12,13], anti-HIV [14,15], antimutator [16,17], anti-inflammatory, anti-leishmanial, anti-malarial [2], antioxidant [18], anticholinergic [19], anti-diabetic [20], and α-glucosidase-inhibitory activity [21], and use as a component of anti-GD2-immunoliposomes for the therapeutic treatment of neuroblastoma [22]. Against this backdrop is diabetes mellitus, a chronic and non-infectious metabolic disease characterized by hyperglycemia, i.e., a high blood glucose level. The prevalence of diabetes mellitus is alarming; about 415 million people worldwide are estimated to have diabetes [23], and this number is expected to increase to about 642 million by 2040 [24,25]. Enzymes such as α-amylase and α-glucosidase hydrolyze carbohydrates into glucose in the blood. α-glucosidase inhibitors thus reduce the absorption of glucose from the small intestine by inhibiting the activity of α-glucosidase secreted by the intestinal epithelium and salivary glands to hydrolyze oligosaccharides into simple sugar. The inhibition of α-amylase and α-glucosidase delays glucose absorption, thereby lowering postprandial blood glucose levels, constituting an effective therapeutic approach to the treatment of diabetes. This capacity is particularly important since there is always a great demand for the design and development of novel, safe, and effective anti-diabetic compounds [20,26,27,28]. Pyrimidine derivatives represent an attractive scaffold with which to develop new and effective lead compounds with potential anti-diabetic activity. Nucleophilic substitutions of chloropyrimidine with amides, amines, alcoholates, sulfides, and Grignard reagents are good applications for the preparation of functionalized pyrimidines [29]. This work provides a detailed approach to the synthesis and characterization of novel pyrimidine derivatives using a one-pot reaction, in a catalyst-free and efficient manner, for the synthesis of 2-amino-4-hydrazinyl-6-methoxy pyrimidine and its subsequent reaction with phenyl isothiocyanate derivatives. However, the sustainability aspect of our synthetic approach, which involves a one-pot, catalyst-free method, aligns with green chemistry principles by reducing reaction steps, eliminating the need for metal catalysts, and minimizing waste generation—making it both environmentally and economically favorable for the synthesis of bioactive molecules [30]. Physical and spectral analyses were used to characterize the synthesized compounds. Furthermore, the biological activity and pharmacological profiles of the pyrimidine derivatives were determined by assessing their activity against the enzymes α-glucosidase and α-amylase. Using this investigational approach, we aimed to develop lead compounds with dual inhibitory effects against both α-amylase and α-glucosidase that would aid in the treatment of diabetes [26,31,32,33]. We describe in this study the synthesis, characterization, potential antidiabetic activity through dual α-glucosidase and α-amylase inhibition, and molecular docking investigations of a new series of potential inhibitors bearing a 2,4-diaminopyrimidine scaffold.

2. Results and Discussion

2.1. Chemistry

Pyrimidine derivatives have been reported to have a wide range of biological actions with anti-microbial [34,35,36], anti-oxidant and anti-cancer [37,38], anti-infective [39], anti-neuroinflammatory [40], anti-Alzheimer [41], anti-diabetic [42,43], anti-tubercular [44], bioactive [45,46], and medicinal approaches [47,48]. Preparation of 2-amino-4-hydrazinyl-6-methoxy pyrimidine (1) was carried out by refluxed 2-amino-4-chloro-6-methoxypyrimidine and hydrazine hydrate in the presence of ethanol as a solvent. The reaction mixture was refluxed at 80–85 °C for 24 h and then left for 24 h at 25 °C. Precipitates were filtered off and then washed with cold ethanol to give compounds (1). The second step involved the reaction of 2-amino-4-hydrazinyl-6-methoxy pyrimidine (1) with phenyl isothiocyanate derivatives at room temperature (Scheme 1).
The assigned structures for synthesized compound (1) are recognized by FTIR, 1H NMR,13C NMR, and mass spectroscopic techniques. While the FTIR spectra showed bands in the region between 2952, 2862 cm−1 for (C-H) stretching, a band in the area (3030, 3060) cm−1 for aromatic (=C-H), and (C=C) stretching bands appeared, respectively. In addition, a new peak appeared for (NH-NH2) at regions (3427, 3139) cm−1, and a band of the (-Cl) at 785–540 group disappeared. Furthermore, 1H NMR spectra have a singlet band δ3.36 related to (-OCH3) and 5.88 for (-CH) pyrimidine, while bands of -NH-, NH2 appeared at δ 4.25, 4.80, and 10.22 ppm. Moreover, the 13C NMR spectra showed a major carbon band at δ 71.3 corresponding to the (-OCH3) group and bands in the region δ93.4–171.1 for pyrimidine carbon. The reaction of hydrazinylpyrimidine (1) with phenyl isothiocyanate derivatives (a1–h1) in chloroform at room temperature for 24 h gave 2-amino-6-methoxypyrimidine derivatives (2–17), respectively. The observed selectivity of the hydrazinyl group (–NH–NH2) over the amino group (–C–NH2) in the reaction of 2-amino-4-hydrazinyl-6-methoxy pyrimidine (1) with phenyl isothiocyanate derivatives can be attributed to both electronic and steric factors. The terminal –NH2 group of the hydrazine moiety is more nucleophilic than the aromatic amino group due to its higher electron density and reduced resonance delocalization with the pyrimidine ring. This makes the hydrazinyl –NH2 more reactive toward electrophiles such as isothiocyanates. Additionally, the hydrazinyl group is positioned more freely in space compared to the ring-bound amino group, reducing steric hindrance during nucleophilic attack. As a result, under the applied reaction conditions, the isothiocyanate preferentially reacts with the hydrazinyl –NH2 group, selectively forming the corresponding thiosemicarbazide intermediate. This behavior is consistent with previously reported chemoselectivity patterns in hydrazine-containing heterocycles [49,50,51,52]. The FTIR spectra of thiourea derivatives (2–17) showed new (-NH-(C=S)-NH) stretching bands. However, compounds showed new bands related to new groups. Furthermore, in the 1H, 13C NMR spectra of (2–17), major bands -OCH3 existed for pyrimidine aromatic protons.

2.2. Biological Evaluation

Antidiabetic Activity

The biological evaluation of the synthesized pyrimidine derivatives against α-glucosidase and α-amylase enzymes is summarized in Table 1. The variations in inhibitory activity among the compounds are likely attributed to the presence of different functional groups. Compound 17 exhibited low inhibitory activity, with IC50 values of 42.19 ± 0.13 µM and 40.16 ± 0.11 µM against both α-glucosidase and α-amylase, compared to the standard drug acarbose (IC50: 09.33 ± 0.04 µM and 0.15 ± 0.06 µM). In contrast, compound 4 showed remarkable inhibitory potential against both enzymes (IC50: 12.16 ± 0.12 µM and 11.13 ± 0.12 µM), as did compound 6, with IC50 values of 16.13 ± 0.11 µM and 15.17 ± 0.07 µM. Compound 9 also displayed significant inhibition, recording IC50 values of 19.11 ± 0.11 µM and 18.16 ± 0.08 µM against α-glucosidase and α-amylase. In the case of compound 11, inhibitory potential against α-glucosidase and α-amylase was as follows: IC50 22.11 ± 0.13 µM and 21.14 ± 0.12 µM, respectively. Similarly, compound 14 showed inhibitory potential against α-glucosidase and α-amylase with IC50 values of 30.12 ± 0.13 µM and 33.18 ± 0.14 µM, respectively. On the other hand, compound 16 exhibited low activity, with IC50 values of 36.14 ± 0.12 µM and 34.24 ± 0.16 µM against both enzymes. Among all tested derivatives, compound 4, featuring a fluoro substituent, displayed the strongest inhibitory effect. This enhanced activity may be attributed to the high electronegativity of the fluorine atom and its favorable interaction within the enzyme active sites.

2.3. Computational Simulation Studies

The primary interpretation of the enzyme-binding assay results was that an electron-withdrawing group is superior to an electron-donating substituent on the phenyl ring (compounds 4, 6, 9, and 11 compared to compound 16), possibly because electron withdrawal increases the hydrogen bonding donor ability of the thiourea nitrogen and helps to increase the quantity of the thiourea tautomer relative to the iminothiol tautomer. Substitution in the meta position yielded active compounds through its inductive effect on the thiourea nitrogen. The nature of the electron withdrawing substituent also contributes to this activity, as groups with better hydrogen acceptor ability were more active compounds (compound 4, compared to compounds 6, 9, and 11). The hydrogen bonding capacity of the fluorine compared to the chlorine, the bromine, and the nitro could explain the relative difference in affinity between those compounds. A more lipophilic substituent also seems to be more favorable when we compare compounds 4, 6, 9, and 11, which have F, Cl, Br, and NO2 substituents, respectively, with compound 17, which has the CN substituent. In conclusion, an electron-withdrawing, relatively lipophilic group with hydrogen bonding capability is favored in the meta position. The affinity of the tested compounds to α-glucosidase and α-amylase was also studied using molecular docking to gain insight into the potential binding interactions that could drive further molecular optimization. The accuracy of Glide in predicting the binding positions for α-glucosidase and α-amylase was validated by redocking the crystal ligands and calculating the relative mean standard deviation (RMSD) for the predicted positions. The results showed good accuracy for Glide in predicting binding to α-glucosidase and α-amylase active sites, with RMSDs of 2.8 and 2.4 for α-glucosidase and α-amylase, respectively. The XP score yielded by Glide together with the free energy of binding (MM-GBSA dG bind) were analyzed and correlated with the experimental IC50s. XP mode is a more advanced and realistic mode of Glide that can screen out false positives, and it is designed to identify active compounds that bind to a particular conformation of a receptor. Explicit water molecules are docked into protein ligand complexes, and descriptors based on the interactions of these water molecules with the ligands and proteins are used as a measure of whether the complex is physically realistic. Penalties are assigned to inadequately solvated structures. GlideScore XP also specifically calculates hydrophobic interactions such that underestimated hydrophobic effects are offset and up to several kcal/mol of additional binding energy can be conferred in favorable cases. GlideScore XP also includes improvements to the scoring of hydrogen bonds as well as the ability to detect buried polar groups, and π-cation and π-π stacking interactions. The MMG-BSA was used to calculate ligand binding energies and ligand strain energies using the Prime module on Maestro. The ranking of the ligands based on the calculated binding energies (via MM-GBSA dG Bind) can be expected to agree reasonably well with a ranking based on experimental binding affinity, particularly in the case of congeneric series. As the MM-GBSA binding energies are approximate free energies of binding, a more negative value indicates stronger binding. MM-GBSA provides reasonable free energy calculations and yields higher enrichment factors than docking calculations [53]. MM-GBSA is therefore more reliable for prioritizing compounds for experimental testing. The MM-GBSA binding free energies were estimated as the total free energies of the protein ligand complex minus the energies of individual ligands and receptors [54,55]. The energy term refers to the sum of the van der Waals, electrostatic, General Born solvation, and surface area energies [56]. The results showed that the MM-GBSA dG binding scores identified the most active and least active compounds (compound 4 compared to compound 17) with respect to α-glucosidase. However, the XP scores were more correlated with the experimental IC50s (compounds 4, 6, and 9 compared to compounds 14, and 17). In the case of α-amylase, the MM-GBSA dG binding scores were more discriminative (compounds 4, 6, and 11 compared to compound 14) than the XP scores. The relatively narrow range of the experimental activity of the compounds and the XP and MM-GBSA scores could be a reason for the imperfect alignment (Table 2).
In this case, the binding interaction analysis is of outmost importance for obtaining better insights into the structure activity relationship of the pyrimidine derivatives for α-glucosidase and α-amylase inhibition. The binding position of the tested compounds showed good alignment with each other as well as with the crystal ligands and the active sites of α-glucosidase and α-amylase active sites (Figure 1). The calculated relative mean standard deviation (RMSD) for the tested pyrimidine analogues showed excellent alignment of the binding poses for the most active compounds, namely compounds 4, 6, 9, and 11, with an RMSD below 2 in both active sites (Table 3). The least active compound, 17, showed the highest deviation in both enzymes. These results suggest that the most active compounds are more capable of engaging in the crucial binding interactions required for the inhibition of both enzymes.
The active site of α-glucosidase (PDB code: 3W37) consists of four subsites (−1, +1, +2, and +3). Subsites −1 and +1 contain two important catalytic residues: Asp 469 and Asp 568. Subsites +2 and +3 contain the following residues: Asp 232, Ile 233, Ala 234, Phe 236, Asn-237, Trp 329, Ile 358, Trp 432, Phe 476, and Phe 601; together, these form a hydrophobic barrier at the entrance of the active site pocket. Trp 329 is a conserved residue that offers catalytic specificity to α-1,6-glucosidic linkages [57]. Compound 4 interacted with the two important catalytic residues, Asp 469, and Asp 568, through hydrogen bonding (Figure 2). The phenyl ring with its lipophilic fluorine substituent was located in the hydrophobic entrance, and potential interactions with π-π staking and halogen bonding with Trp 239 were noted. This finding supports the primary structure activity analysis that postulated that a lipophilic substituent is more favored at this position. It seems that in our pyrimidine derivatives, the phenyl ring and its substituent facilitate the entry of the compounds into the active site and their stability therein and help in acquiring the proper orientation of the di- amino pyrimidine scaffold to interact with the key catalytic residues. Potential hydrogen bonding was also noted between the primary amino group and Asp 232 and the methoxy group and Ala 234.
The active site of α-amylase contains two important catalytic residues, Asp 197 and Glu 233. Asp 197 is known to act as the catalytic nucleophile in the hydrolysis reaction catalyzed by α-amylase, while Glu 233 acts as the acid-base catalyst. Asp 300 is another important residue that optimizes the orientation of the substrate in the active site [58]. Compound 4 formed two important hydrogen bonds with the two catalytic residues, Asp 197 and Alu 233. The phenyl ring, as depicted in α-glucosidase, interacted with Trp 59 at the entrance of the active site through π-π staking and halogen bonds. Additional hydrogen bonds were formed with other key residues in the active site, including Asp 300 and Gln 63. In the previous discussion, one can note a close similarity regarding our pyrimidine derivatives’ inhibition mechanisms for both enzymes. This finding is very compatible with the aligned activities of 147 of our pyrimidine derivatives for both enzymes (Figure 3).
Furthermore, the binding of the least active compounds showed different orientations in both enzymes with the phenyl ring and its more hydrophilic cyano substituent, and unlike the fluoro phenyl in compound 4, it occurred far from the hydrophobic gates. Compound 17 engaged in hydrogen bonding with Asp 232 and Asp 568 in α-glucosidase and with Gln 62 in α-amylase, interactions that are not as crucial as the interactions engaged in in the case of compound 4. This finding explains the lower activity of compound 17 attributed to its low stability and low-affinity orientation in the active sites of both enzymes (Figure 4).
Potential electrostatic interactions are represented as yellow dotted lines and measured in Angstroms. Three-dimensional representations of the binding interactions between compound 17 and the active site of α-amylase (PDB code: 4GQR) and the interacting residues are shown as digital representations in the form of cartoon, sticks (carbon atoms colored in magenta), and sticks (carbon atom colored in green), respectively. Potential electrostatic interactions are represented as yellow dotted lines and are measured in Angstrom.
In conclusion, our research has identified 2,4-diaminopyrimidine as a new scaffold for the dual inhibition of α-glucosidase and α-amylase. This scaffold is essential in binding the key catalytic residues at the active sites of α-glucosidase and α-amylase. It should be attached to a lipophilic aromatic system to give it optimal stability and the best orientation at the active sites. The substitution of a lipophilic substituent on the phenyl ring increases its activity. The spacer between the di-amino pyrimidine scaffold and the aromatic ring should contain heteroatoms with good hydrogen bonding ability.

3. Materials and Methods

3.1. General Methods

All chemicals were supplied from Sigma-Aldrich (St. Louis, MO, USA). Melting points were determined via the Stuart SMP10 Digital Advanced MP apparatus (Cole-Parmer Ltd., Stone, UK) and are uncorrected. FTIR spectra were carried out on PerkinElmer (FTIR spectrometer, PerkinElmer Inc., Waltham, MA, USA), which mixed without using anhydrous KBr. The NMR spectra were recorded by JEOL RESONANCE spectrometer (Akishima, Japan) 500 MHZ by using DMSO-d6 as the solvent and chemical shifts (δ) and were recorded in parts per million (ppm) using tetramethyl silane (TMS) as the internal standard. The mass spectra were carried out on LC/MS spectroscopy (LCMS-8040 Shimadzu, Kyoto, Japan, model CAT-30A). Serial no. L20574900241 AE, 220–240 v~50/60 HZ 300 VA was used to record LCMS spectral data for samples. Elemental microanalysis was done on a Carlo Erba analyzer model 110 (Carlo Erba Instruments, Milan, Italy). Also used were α-amylase Assay Kit (Colorimetric) ab102523 (Abcam, Cambridge, MA, USA), α-glucosidase Activity Assay Kit (Colorimetric) ab102523 (Abcam, Cambridge, MA, USA), and Elisa: BioTek (Winooski, VT, USA) introduces Synergy Neo2 high performance Multi-Mode Microplate Reader.

3.2. General Procedures of Synthesis New Compounds

3.2.1. Synthesis of 2-Amino-4-hydrazinyl-6-methoxypyrimidine (1)

An amount of 5.0 g (31.33 mmol) of 2-Amino-4-chloro-6-methoxy-pyrimidine was weighed and transferred into a round-bottomed flask with 150 mL of ethanol and left for stirring, then 50 mL hydrazine hydrate were added to the reaction solution. The reaction mixture was refluxed overnight in oil bath. After reaction completion, the product was transferred into a beaker and left for evaporation. The obtained product was washed with diethyl ether (30 mL 3 times) and dried at room temperature and had the following characteristics: White powder; yield (88.03%); m.p.: 238–239 °C; FT-IR (KBr, ν, cm−1): 3427, 3139 (-NHNH2), 3398, 3343 (-N-Hst), 1582 (-N-Hbend), 1079 (C-Nst Ar), 3030, 3060 (=C-H st), 2952, 2862 (-C-Hst), 1265 (-O-CH3st); 1H NMR, δ (ppm) in DMSO-d6: 3.36 (s, 3H, -OCH3), 4.25 (br, 2H, -NH2), 4.80 (br, 2H, -NH2 Pyrimidine), 5.88 (s, 1H, -CHPyrimidine), 10.22 (br, 1H, -NH-); 13C NMR, δ (ppm) in DMSO-d6: 71.3 (1C, -OCH3), 93.4 (1C, -C=CH-C=N-Pyrimidine), 163.3 (1C, =C-NH2 Pyrimidine), 168.9 (1C, =C-OCH3 Pyrimidine), 171.1 (1C, =C-NH-NH2 Pyrimidine); MS (m/z): 155.0 (M+, 100%); Anal. calcd. for C5H9N5O (MW:155.16): C, 38.70; H, 5.85; N, 45.14; found: C, 38.71; H, 5.87; N, 45.15.

3.2.2. Reaction of 2-Amino-4-hydrazinyl-6-methoxypyrimidine with Phenyl Isothiocyanate Derivatives to Give Compounds (2–17)

An amount of 0.086 g (0.5 mmol) of 2-amino-4-hydrazinyl-6-methoxypyrimidine (1) was weighed and transferred into a 25 mL round-bottomed flask along with 10 mL of chloroform. Then, 0.6 mmol of phenyl isothiocyanate, as given in the list (0.081 g) of phenyl isothiocyanate (a), (0.092 g) of 2-fluorophenyl isothiocyanate (b1), 3-fluorophenyl isothiocyanate (b2), 4-fluorophenyl isothiocyanate (b3), (0.102 g) of 3-chlorophenyl isothiocyanate (c1), 4-chlorophenyl isothiocyanate (c2), (0.128 g) of 2-bromophenyl isothiocyanate (d1), 3-bromophenyl isothiocyanate (d2), 4-bromophenyl isothiocyanate (d3), (0.108 g) of 3-nitrophenyl isothiocyanate (e1), 4-nitrophenyl isothiocyanate (e2), (0.099 g) of 2-methoxyphenyl isothiocyanate (f1), 3-methoxyphenyl isothiocyanate (f2), 4-methoxyphenyl isothiocyanate (f3), (0.096 g) of 3-cyanophenyl isothiocyanate (g1), and (0.090 g) of p-tolyl isothiocyanate (h1), was added to the flask, and the reaction mixture was stirred for 24 h at room temperature. After 24 h, the reaction mixture was transferred into a beaker, and the solvent was evaporated completely. Products were washed with diethyl ether (20–30 mL), dried at room temperature, and stored at 4 °C. The following were produced:
2-(2-Amino-6-methoxypyrimidin-4-yl)-N-phenylhydrazine-carbothioamide (2)
White powder; yield (64.29%); m.p.: 188–189 °C; FT-IR (KBr, ν, cm−1): 3180, 3300 (N-H st), 1470 (C-N), 726 (C=S), 3498, 3344 (-N-Hst), 1652 (-N-Hbend), 1064 (C-Nst Ar), 3029, 3060 (=C-Hst), 2960, 2862 (-C-Hst), 1231(-OCH3st); 1H NMR, δ (ppm) in DMSO-d6: 3.73 (s, 3H, -OCH3), 5.39 (br, 2H,-NH2), 9.48 (br, 2H, =NH-NH-), 10.14 (br, 1H, -NH-CS), 5.80 (s, 1H, =CH-Pyrimidine), 7.12–7.85 (m, 5H,=CH-Phenyl); 13C NMR, δ (ppm) in DMSO-d6: 53.2 (1C, -OCH3), 70.9 (1C, -C=CH-C=N-Pyrimidine), 125.7, 128.4 (5C, =C-, =CH-Phenyl), 139.8 (1C, =C-NH-Phenyl), 160.40 (1C, =C-NH2 Pyrimidine), 163.2 (1C, =C-NH-N=Pyrimidine), 166.1 (1C, =C-OCH3,Pyrimidine), 169.4 (1C, -C=S); MS (m/z): 290.00 (M+, 100.0%); Anal. calcd. for C12H14N6OS (MW: 290.34); C, 49.64; H, 4.86; N, 28.95; S, 11.04%; found: C, 49.64; H, 4.85; N, 28.98; S, 11.02%.
2-(2-Amino-6-methoxypyrimidin-4-yl)-N-(2-fluorophenyl)-hydrazine Carbothioamide (3)
Beige powder; yield (74.60%); m.p.: 200–201 °C; FT-IR (KBr, ν, cm−1): 3180, 3300 (N-Hst), 1428 (C-N), 783 (C=S), 3498, 3344 (-N-Hst), 1582 (-N-Hbend); 1074 (C-NstAr), 3029, 3060 (=C-Hst), 2960, 2862 (-C-Hst), 1264(-OCH3st), 1100 (C-F); 1H NMR, δ (ppm) in DMSO-d6: 3.74 (s, 3H, -OCH3), 6.03 (s, 1H, =CH-Pyrimidine), 7.19–7.68 (m, 4H, =CH-Phenyl), 4.74 (br, 2H, -NH2), 8.85 (br, 2H, =NH-NH-), 9.48 (br, 1H, -NH-CS); 13C NMR, δ (ppm) in DMSO-d6: 53.3 (1C, -OCH3), 70.5 (1C, -C=CH-Pyrimidine), 114.0, 124.2, 127.8, 129.8 (5C, =C-, =CH-Phenyl), 156.1 (1C, =C-F Phenyl), 159.4 (1C, =C-NH2 Pyrimidine), 163.1 (1C, =C-NH-N=Pyrimidine), 165.8 (1C, =C-OCH3 Pyrimidine), 182.2 (1C, -C=S); MS (m/z): 308.0 (M+, 100.0%); Anal. calcd. for C12H13FN6OS (MW: 308.33); C, 46.74; H, 4.25; N, 27.26; S, 10.40; F, 6.16%; found: C, 46.77; H, 4.24; N, 27.27; S, 10.41; F, 6.17%.
2-(2-Amino-6-methoxypyrimidin-4-yl)-N-(3-fluorophenyl)hydrazine Carbothioamide (4)
Beige powder; yield (57.38%); m.p.: 184–185 °C; FT-IR (KBr, ν, cm−1): 3170, 3301(N-Hst), 1430 (C-N), 784 (C=S), 3488, 3341 (-N-Hst), 1588 (-N-Hbend), 1070 (C-NstAr), 3026, 3066 (=C-Hst), 2960, 2860 (-C-Hst), 1258 (-OCH3st), 1100 (C-F); 1H NMR, δ (ppm) in DMSO-d6: 3.72 (s, 3H, -OCH3), 5.92 (s, 1H,=CH-Pyrimidine), 6.91–7.91 (m, 4H,=CH-Phenyl), 4.02 (br, 2H, -NH2), 9.02 (br, 2H, =NH-NH-), 10.20 (br, 1H, -NH-CS); 13C NMR, δ (ppm) in DMSO-d6: 52.9 (1C, -OCH3), 70.4 (1C, -C=CH-Pyrimidine), 112.0, 113.6, 129.7, 130.4 (5C, =C-, =CH-Phenyl), 159.3 (1C, =C-FPhenyl), 163.1 (1C, =C-NH2 Pyrimidine), 165.2 (1C, =C-NH-N=Pyrimidine), 171.1 (1C, =C-OCH3 Pyrimidine), 181.4 (1C, -C=S); MS (m/z): 308.0 (M+, 100.0%); Anal. calcd. For C12H13FN6OS (MW: 308.33); C, 46.74; H, 4.25; N, 27.26; S, 10.40; F, 6.16%; found: C, 46.77; H, 4.24; N, 27.27; S, 10.41; F, 6.17%.
2-(2-Amino-6-Methoxypyrimidin-4-yl)-N-(4-Fluorophenyl)Hydrazine Carbothioamide (5)
Pink powder; yield (53.56%); m.p.: 180–181 °C; FT-IR (KBr, ν, cm−1): 3177, 3300 (N-Hst), 1428 (C-N), 784 (C=S), 3490, 3334 (-N-Hst), 1587 (-N-Hbend); 1073 (C-NstAr), 3029, 3060 (=C-Hst), 2960, 2862 (-C-Hst), 1254 (-OCH3st), 1100 (C-F); 1H NMR, δ (ppm) in DMSO-d6: 3.73 (s, 3H, -OCH3), 5.75 (s, 1H, =CH-Pyrimidine), 7.07–7.67 (m, 4H, =CH-Phenyl), 4.41 (br, 2H, -NH2), 8.80 (br, 2H, =NH-NH-), 9.77 (br, 1H, -NH-CS); 13C NMR, δ(ppm) in DMSO-d6: 53.1 (1C, -OCH3), 71.0 (1C, -C=CH-Pyrimidine), 115.0, 128.0, 136.0 (5C, =C-, =CH-Phenyl), 158.8 (1C, =C-F Phenyl), 160.8 (1C, =C-NH2 Pyrimidine), 163.2 (1C, =C-NH-N=Pyrimidine); 166.3 (1C, =C-OCH3 Pyrimidine), 181.0 (1C, -C=S); MS (m/z): 308.0 (M+, 100.0%); Anal. calcd. for C12H13FN6OS (MW: 308.33); C, 46.74; H, 4.25; N, 27.26; S, 10.40; F, 6.16%; found: C, 46.77; H, 4.24; N, 27.27; S, 10.41; F, 6.17%.
2-(2-Amino-6-methoxypyrimidin-4-yl)-N-(3-chlorophenyl) Hydrazine Carbothioamide (6)
White powder; yield (70.09%); m.p.: 180.5–182 °C; FT-IR (KBr, ν, cm−1): 3177, 3299 (N-Hst), 1429 (C-N), 783 (C=S), 3498, 3344 (-N-Hst),1589 (-N-Hbend),1074 (C-NstAr), 3029, 3060 (=C-Hst), 2960, 2862 (-C-Hst), 1260 (-OCH3st),700 (-Cl); 1H NMR, δ (ppm) in DMSO-d6: 3.73 (s, 3H, -OCH3), 6.25 (s, 1H, =CH-Pyrimidine), 7.15–8.08 (m, 4H, =CH-Phenyl), 5.15 (br, 2H, -NH2), 9.55 (br, 2H, =NH-NH-), 10.21 (br, 1H, -NH-CS); 13C NMR, δ (ppm) in DMSO-d6: 53.2 (1C, -OCH3), 70.0 (1C, -C=CH-Pyrimidine), 116.80, 124.0, 126.3, 129.8 (5C, =C-, =CH-Phenyl), 133.1 (1C, =C-Cl Phenyl), 141.3 (1C, =C-NH2 Pyrimidine), 158.0 (1C, =C-NH-N=Pyrimidine), 164.3 (1C, =C-OCH3 Pyrimidine), 181.2 (1C, -C=S); MS (m/z): 324.0 (M+, 79.93%); Anal. calcd. for C12H13ClN6OS (MW: 324.79); C, 44.38; H, 4.03; N, 25.88; S, 9.87; Cl, 10.92%; found: C, 44.40; H, 4.01; N, 25.87; S, 9.88; Cl, 10.93%.
2-(2-Amino-6-methoxypyrimidin-4-yl)-N-(4-chlorophenyl)-hydrazine Carbothioamide (7)
Beige powder; yield (52.51%); m.p.: 199–200 °C; FT-IR (KBr, ν, cm−1): 3170, 3301 (N-Hst), 1430 (C-N); 785 (C=S), 3488, 3341 (-N-Hst), 1583 (-N-Hbend), 1050 (C-NstAr), 3027, 3068 (=C-Hst), 2941, 2864 (-C-Hst), 1258 (-OCH3st), 677 (-Cl); 1H NMR, δ (ppm) in DMSO-d6: 3.73 (s, 3H, -OCH3), 5.39 (s, 1H,=CH-Pyrimidine), 7.13–7.70 (m, 4H,=CH-Phenyl), 4.44 (br, 2H, -NH2), 8.59 (br, 2H, =NH-NH-), 9.75 (br, 1H, -NH-CS); 13C NMR, δ (ppm) in DMSO-d6: 53.1 (1C, -OCH3), 70.70 (1C, -C=CH-,Pyrimidine), 126.1, 128.2 (5C, =C-, =CH-Phenyl), 147.4 (1C, =C-Cl, Phenyl), 160.1 (1C, =C-NH2 Pyrimidine), 163.2 (1C, =C-NH-N=Pyrimidine), 165.9 (1C, =C-OCH3 Pyrimidine), 186.0 (1C, -C=S); MS (m/z): 324.0 (M+, 100.0%); Anal. calcd. for C12H13ClN6OS (MW: 324.79); C, 44.38; H, 4.03; N, 25.88; S, 9.87; Cl, 10.92%; found: C, 44.40; H, 4.01; N, 25.87; S, 9.88; Cl, 10.93%.
2-(2-Amino-6-methoxypyrimidin-4-yl)-N-(2-bromophenyl)-hydrazine Carbothioamide (8)
White powder; yield (69.22%); m.p.: 210–211 °C; FT-IR (KBr, ν, cm−1): 3109, 3300 (N-Hst), 1428 (C-N), 784 (C=S), 3490, 3350 (-N-Hst), 1587 (-N-Hbend), 1073 (C-NstAr), 3029, 3060 (=C-Hst), 2983, 2882 (-C-Hst), 1254 (-OCH3st), 510 (-Br); 1H NMR, δ (ppm) in DMSO-d6: 3.73 (s, 3H, -OCH3), 5.35 (s, 1H, =CH-Pyrimidine), 7.7.08–7.81 (m, 4H, =CH-Phenyl), 4.90 (br, 2H, -NH2), 9.49 (br, 2H, =NH-NH-), 9.88 (br, 1H, -NH-CS); 13C NMR, δ (ppm) in DMSO-d6: 56.0 (1C, -OCH3), 73.6 (1C, -C=CH-Pyrimidine), 120.7 (1C, =C-Br Phenyl), 127.6, 129.0, 132.5, 138.1 (5C, =C-, =CH-Phenyl), 158.0 (1C, =C-NH2 Pyrimidine), 163.4 (1C, =C-NH-N=Pyrimidine), 164.2 (1C, =C-OCH3 Pyrimidine), 181.3 (1C, -C=S); MS (m/z): 369.0 (M+, 100.0%); Anal. calcd. for C12H13BrN6OS (MW: 369.24); C, 39.03; H, 3.55; N, 22.76; S, 8.68; Br, 21.64%; found: C, 39.05; H, 3.57; N, 22.75; S, 8.66; Br, 21.66%.
2-(2-Amino-6-methoxypyrimidin-4-yl)-N-(3-bromophenyl)-hydrazine Carbothioamide (9)
White powder; yield (66.72%); m.p.: 187.5–188 °C; FT-IR (KBr, ν, cm−1): 3167, 3300 (N-Hst), 1427 (C-N), 784 (C=S), 3490, 3350 (-N-Hst), 1588 (-N-Hbend), 1053 (C-Nst Ar), 3029, 3060 (=C-Hst), 2983, 2862 (-C-Hst), 1254 (-OCH3st), 510 (-Br); 1H NMR, δ (ppm) in DMSO-d6: 3.73 (s, 3H, -OCH3), 5.25 (s, 1H, =CH-Pyrimidine), 6.78–7.77 (m, 4H, =CH-Phenyl), 4.86 (br, 2H, -NH2), 9.03 (br, 2H, =NH-NH-), 10.23 (br, 1H, -NH-CS); 13C NMR, δ (ppm) in DMSO-d6: 53.2 (1C, -OCH3), 70.3 (1C, -C=CH-Pyrimidine), 120.7 (1C, =C-Br Phenyl), 124.4, 127.7, 130.2, 131.0 (5C, =C-, =CH-Phenyl), 158.7 (1C, =C-NH2 Pyrimidine), 165.0 (1C, =C-NH-N=Pyrimidine), 171.1 (1C, =C-OCH3 Pyrimidine), 181.0 (1C, -C=S); MS (m/z): 369.0 (M+, 100.0%); Anal. calcd. for C12H13BrN6OS (MW: 369.24); C, 39.03; H, 3.55; N, 22.76; S, 8.68; Br, 21.64%; found: C, 39.05; H, 3.57; N, 22.75; S, 8.66; Br, 21.66%.
2-(2-Amino-6-methoxypyrimidin-4-yl)-N-(4-bromophenyl)-hydrazine Carbothioamide (10)
Beige powder; yield (36.57%); m.p.: 189–189.5 °C; FT-IR (KBr, ν, cm−1): 3177, 3300 (N-Hst), 1431 (C-N), 784 (C=S), 3490, 3334 (-N-Hst), 1583 (-N-Hbend), 1070 (C-NstAr), 3029, 3060 (=C-Hst), 2940, 2862 (-C-Hst), 1267 (-OCH3st), 523 (-Br); 1H NMR, δ (ppm) in DMSO-d6: 3.73 (s, 3H, -OCH3), 5.39 (s, 1H, =CHPyrimidine), 7.24–7.87 (m, 4H, =CH-Phenyl), 4.49 (br, 2H, -NH2), 9.01 (br, 2H, =NH-NH-), 10.22 (br, 1H, -NH-CS); 13C NMR, δ (ppm) in DMSO-d6: 53.1 (1C, -OCH3), 70.8 (1C, -C=CH-Pyrimidine), 120.4 (1C, =C-Br,Phenyl), 128.0, 131.1 (5C, =C-, =CH-Phenyl), 160.1 (1C, =C-NH2 Pyrimidine), 163.2 (1C, =C-NH-N=Pyrimidine), 165.8 (1C, =C-OCH3 Pyrimidine), 171.0 (1C, -C=S); MS (m/z): 369.0 (M+, 100.0%); Anal. calcd. for C12H13BrN6OS (MW: 369.24); C, 39.03; H, 3.55; N, 22.76; S, 8.68; Br, 21.64%; found: C, 39.05; H, 3.57; N, 22.75; S, 8.66; Br, 21.66%.
2-(2-Amino-6-methoxypyrimidin-4-yl)-N-(3-nitrophenyl)hydrazine Carbothioamide (11)
Yellow powder; yield (72.05%); m.p.: 173–174 °C; FT-IR (KBr, ν, cm−1): 3180, 3298 (N-Hst),1426 (C-N), 780 (C=S), 3480, 3335 (-N-Hst), 1580 (-N-Hbend), 1072 (C-NstAr), 3025, 3058 (=C-Hst), 2960, 2862 (-C-Hst). 1254 (-OCH3st), 1518, 1327(-NO2); 1H NMR, δ (ppm) in DMSO-d6: 3.73 (s, 3H, -OCH3), 5.38 (s, 1H, =CH-Pyrimidine), 7.35–8.04 (m, 4H, =CH-Phenyl), 4.40 (br, 2H, -NH2), 8.85 (br, 3H, =NH-NH-), 10.42 (br, 1H, -NH-CS); 13C NMR, δ (ppm) in DMSO-d6: 53.1 (1C, -OCH3), 70.1 (1C, -C=CH-Pyrimidine), 111.7, 123.6, 129.1, 129.5 (5C, =C-, =CH-Phenyl), 148.6 (1C, =C-NO2, Phenyl), 162.9 (1C, =C-NH2 Pyrimidine), 164.6 (1C, =C-NH-N=Pyrimidine), 165.3 (1C, =C-OCH3 Pyrimidine); 171.4 (1C, -C=S); MS (m/z): 335.0 (M+, 100.0%); Anal. calcd. for C12H13N7O3S (MW: 335.34); C, 42.98; H, 3.91; N, 29.24; S, 9.56%; found: C, 42.99; H, 3.91; N, 29.20; S, 9.57%.
2-(2-Amino-6-methoxypyrimidin-4-yl)-N-(4-nitrophenyl)hydrazine Carbothioamide (12)
Orange powder; yield (73.35%); m.p.: 179–180 °C; FT-IR (KBr, ν, cm−1): 3177, 3300 (N-Hst), 1428 (C-N), 784 (C=S), 3486, 3334 (-N-Hst), 1586 (-N-Hbend), 1073 (C-NstAr), 3029, 3060 (=C-Hst), 2960, 2861(-C-Hst), 1254 (-OCH3st), 1518, 1327 (-NO2); 1H NMR, δ (ppm) in DMSO-d6: 3.73 (s, 3H, -OCH3), 5.39 (s, 1H, =CH-Pyrimidine), 7.13–8.16 (m, 4H, =CH-Phenyl), 4.42 (br, 2H, -NH2), 9.03 (br, 2H, =NH-NH-), 10.13 (br, 1H, -NH-CS); 13C NMR, δ (ppm) in DMSO-d6: 53.3 (1C, -OCH3), 70.1 (1C, -C=CH-Pyrimidine), 116.7, 124.0, 125.5 (5C, =C-, =CH-Phenyl), 148.6 (1C, =C-NO2, Phenyl), 153.3 (1C, =C-NH2 Pyrimidine), 164.6 (1C, =C-NH-N=Pyrimidine), 165.3 (1C, =C-OCH3 Pyrimidine), 171.4 (1C, -C=S); MS (m/z): 335.0 (M+, 52.25%); Anal. calcd. for C12H13N7O3S (MW: 335.34); C, 42.98; H, 3.91; N, 29.24; S, 9.56%; found: C, 42.99; H, 3.91; N, 29.20; S, 9.57%.
2-(2-Amino-6-methoxypyrimidin-4-yl)-N-(2-methoxyphenyl)-hydrazine Carbothioamide (13)
Purple powder; yield (87.83%); m.p.: 169–170 °C; FT-IR (KBr, ν, cm−1): 3174, 3300 (N-Hst), 1428 (C-N), 784 (C=S), 3490, 3334 (-N-Hst), 1582 (-N-Hbend), 1072 (C-NstAr), 3030, 3060 (=C-Hst), 2962, 2862 (-C-Hst), 1254 (-OCH3st); 1H NMR, δ (ppm) in DMSO-d6: 3.73 (s, 6H, -OCH3), 6.12 (s, 1H, =CH-Pyrimidine), 6.86–7.79 (m, 4H, =CH-Phenyl), 4.01 (br, 2H, -NH2), 8.62 (br, 2H, =NH-NH-), 9.78 (br, 1H, -NH-CS); 13C NMR, δ (ppm) in DMSO-d6: 53.2 (2C, -OCH3), 70.3 (1C, -C=CH-Pyrimidine), 116.3, 121.8, 124.4, 127.7 (5C, =C-, =CH-Phenyl), 155.8 (1C, =C-OCH3-Phenyl), 158.5 (1C, =C-NH2 Pyrimidine), 164.4 (1C, =C-NH-N=Pyrimidine), 171.2 (1C, =C-OCH3 Pyrimidine), 181.2 (1C, -C=S); MS (m/z): 320.0 (M+, 90.0%); Anal. calcd. for C13H16N6O2S (MW: 320.37); C, 48.74; H, 5.03; N, 26.23; S, 10.01%; found: C, 48.73; H, 5.01; N, 26.21; S, 10.00%.
2-(2-Amino-6-methoxypyrimidin-4-yl)-N-(3-methoxyphenyl)-hydrazine Carbothioamide (14)
Purple powder; yield (73.85%); m.p.: 182.5–184 °C; FT-IR (KBr, ν, cm−1): 3177, 3243 (N-Hst), 1428 (C-N), 782 (C=S), 3490, 3334 (-N-Hst), 1585 (-N-Hbend); 1073 (C-NstAr), 3029, 3060 (=C-Hst), 2960, 2862 (-C-Hst), 1250 (-OCH3st); 1H NMR, δ (ppm) in DMSO-d6: 3.73 (s, 6H, -OCH3), 5.95 (s, 1H, =CH-Pyrimidine), 7.16–8.90 (m, 4H, =CH-Phenyl), 4.68 (br, 2H, -NH2), 8.90, 8.42 (br, 2H, =NH-NH-), 9.67 (br, 1H, -NH-CS); 13C NMR, δ (ppm) in DMSO-d6: 55.5 (2C, -OCH3), 70.6 (1C, -C=CH-Pyrimidine), 110.8, 129.1 (5C, =C-, =CH Phenyl), 158.8 (1C, =C-OCH3-Phenyl), 159.4 (1C, =C-NH2 Pyrimidine), 163.1 (1C, =C-NH-N=Pyrimidine), 165.4 (1C, =C-OCH3 Pyrimidine), 181.0 (1C, -C=S); MS (m/z): 320.0 (M+, 100.0%); Anal. calcd. for C13H16N6O2S (MW: 320.37); C, 48.74; H, 5.03; N, 26.23; S, 10.01%; found: C, 48.73; H, 5.01; N, 26.21; S, 10.00%.
2-(2-Amino-6-methoxypyrimidin-4-yl)-N-(4-methoxyphenyl) Hydrazine Carbothioamide (15)
Beige powder; yield (69.55%); m.p.: 209–210 °C; FT-IR (KBr, ν, cm−1): 3171, 3300 (N-Hst), 1425 (C-N), 784 (C=S), 3490, 3334 (-N-Hst),1582 (-N-Hbend), 1070 (C-NstAr), 3025, 3058 (=C-Hst), 2960, 2862 (-C-Hst), 1250 (-OCH3st); 1H NMR, δ (ppm) in DMSO-d6: 3.73 (s, 6H, -OCH3), 5.39 (s, 1H, =CH-Pyrimidine), 6.83–7.25 (m, 4H, =CH-Phenyl), 4.36 (br, 2H, -NH2), 8.53 (br, 2H, =NH-NH-), 9.58 (br, 1H, -NH-CS); 13C NMR, δ (ppm) in DMSO-d6: 55.5 (2C, -OCH3), 70.6 (1C, -C=CH-Pyrimidine), 110.8, 117.4, 129.1 (5C, =C-, =CH-Phenyl), 140.9 (1C, =C-OCH3-Phenyl), 159.4 (1C, =C-NH2 Pyrimidine), 163.1 (1C, =C-NH-N=Pyrimidine), 165.4 (1C, =C-OCH3 Pyrimidine), 181.0 (1C, -C=S); MS (m/z): 320.0 (M+, 65.60%); Anal. calcd. for C13H16N6O2S (MW: 320.37); C, 48.74; H, 5.03; N, 26.23; S, 10.01%; found: C, 48.73; H, 5.01; N, 26.21; S, 10.00%.
2-(2-Amino-6-methoxypyrimidin-4-yl)-N-(p-tolyl)hydrazine Carbothioamide (16)
Brown powder; yield (57.53%); m.p.: 198–199 °C; FT-IR (KBr, ν, cm−1): 3177, 3300 (N-Hst), 1428 (C-N), 784 (C=S), 3490, 3334 (-N-Hst), 1581 (-N-Hbend), 1070 (C-NstAr), 3029, 3060 (=C-Hst), 2960, 2862 (-C-Hst), 1266 (-OCH3st); 1H NMR, δ (ppm) in DMSO-d6: 1.81 (s, 3H, -CH3), 3.73 (s, 3H, -OCH3), 5.36 (s, 1H,=CH-Pyrimidine), 7.02–7.43 (m, 4H,=CH-Phenyl), 4.26 (br, 2H, -NH2), 8.53(br, 2H, =NH-NH-), 9.56 (br, 1H, -NH-CS); 13C NMR, δ (ppm) in DMSO-d6: 21.0 (1C, -CH3), 53.2 (1C, -OCH3), 71.1 (1C, -C=CH-Pyrimidine), 125.6, 128.9, 155.8 (5C, =C-, =CH-Phenyl), 147.3 (1C, =C-CH3Phenyl), 160.8 (1C, =C-NH2 Pyrimidine), 163.3 (1C, =C-NH-N=Pyrimidine), 166.3 (1C, =C-OCH3 Pyrimidine), 186.0 (1C, -C=S); MS (m/z): 304.0 (M+, 100.0%); Anal. calcd. for C13H16N6OS (MW: 304.37); C, 51.30; H, 5.30; N, 27.61; S, 10.53%; found: C, 50.31; H, 5.31; N, 27.61; S, 10.51%.
2-(2-Amino-6-methoxypyrimidin-4-yl)-N-(3-cyanophenyl)hydrazine Carbothioamide (17)
Brown powder; yield (61.39%); m.p.: 174–175 °C; FT-IR (KBr, ν, cm−1): 3170, 3300 (N-Hst), 1428 (C-N), 784 (C=S), 3490, 3334 (-N-Hst), 1578 (-N-Hbend), 1073 (C-NstAr), 3025, 3063 (=C-Hst), 2962, 2866 (-C-Hst), 1254 (-OCH3st), 2232, 1486 (-CNst); 1H NMR, δ (ppm) in DMSO-d6: 3.73 (s, 3H, -OCH3), 5.39 (s, 1H, =CH-Pyrimidine), 7.01–7.88 (m, 4H, =CH-Phenyl), 4.89, (br, 2H, -NH2), 8.67 (br, 2H, =NH-NH-), 9.94 (br, 1H,-NH-CS); 13C NMR, δ (ppm) in DMSO-d6: 53.3 (1C, -OCH3), 70.2 (1C, -C=CH-Pyrimidine), 111.3 (1C, -C-CN, Phenyl), 122.1 (1C, -CN), 128.6, 129.9, 130.4 (5C, =C-, =CH-Phenyl), 143.9 (1C, =C-NH2 Pyrimidine), 158.7 (1C, =C-NH-N=Pyrimidine), 164.9 (1C, =C-OCH3 Pyrimidine), 186.0 (1C, -C=S); MS (m/z): 315.0 (M+, 100.0%); Anal. calcd. for C13H13N7OS (MW: 315.35); C, 49.51; H, 4.16; N,31.09; S, 10.17%; found: C, 49.52; H, 4.16; N, 31.12; S, 10.19%.

3.3. Biological Activity as Antidiabetic Activity of Most of Synthetic Compound of Pyrimidine Derivatives

3.3.1. α-Amylase Activity Assay

The α-amylase activity assay was performed according to our previous reported work [31] by mixing samples (50 μL) and the substrate solution (50 μL), adding an assay buffer (50 μL) and reaction mixture (50 μL) to each well, and then measuring absorbance at room temperature, against acarbose as the standard drug. The % inhibition was calculated as follows:
% Inhibition = (Absorbancecontrol − Absorbancecompound) × 100/Absorbancecontrol

3.3.2. α-Glucosidase Activity Assay

The α-glucosidase activity assay was conducted as we reported earlier [31]. Samples (50 μL) were added to 96 wells, and the volume was adjusted to 100 μL/well with an assay buffer. For the reaction, 50 μL of reaction mix for each reaction were performed by adding assay buffer 47 μL and substrate mix 3 μL. An amount of 50 μL of the reaction mix was added into each well, it was mixed thoroughly, and the absorbance was recorded at room temperature, against acarbose as the standard drug.

3.4. Computational Simulation Studies

The computational studies were carried out using the Maestro module (version 11.8) of Schrodinger software suite (Schrodinger, LLC., New York, NY, USA, 2018) [53].

3.4.1. Crystal Structures

The X-ray coordinates of α-glucosidase and α-amylase (PDB IDs: 3W37 and 4GQR, respectively) were obtained from the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB) [54].

3.4.2. Protein Preparation

The PDB structures were prepared for docking using the Protein Preparation Workflow. The preparation and minimization process were carried out at a pH of 7.4, and ionization states were adjusted. Polar hydrogens were added, and non-essential water molecules were excluded from the structures. The targets’ structures were finally minimized by using an OPLS3 force field with a default value for rmsd of 0.30 Å for non-hydrogen atoms [55].

3.5. Receptor Grid Generation

The receptor grids were positioned at the center of the bound ligand for each receptor with a 1.00 van der Waals radius along with a cutoff of 0.25 for partial charges. A grid box of 20 Å3 was generated for the binding site using default parameters and without any constraints.

3.5.1. Ligand Library Preparation

The ligands to be docked were prepared and optimized for docking using LigPrep by generating the most likely ionization states at a pH of 7 ± 1 while keeping the original ionization state intact. During this process, the ligands’ structures were optimized with the OPLS3 force field. The produced ligands’ conformations were used for docking without further modifications.

3.5.2. Validation of Molecular Docking

The validation of the molecular docking was performed by calculating the accuracy of the predicted conformations to match the experimental conformations [56,57,58]. The crystallographic ligands were docked into their respective targets using the same docking criteria used for the prepared ligands. The docked position with the lowest binding energy was then aligned with the conformation of the crystallographic structure using Maestro’s structure superimposition tool, and the root mean square deviation (RMSD) of the alignments was then calculated.

3.5.3. Molecular Docking

The extra precision mode (XP) on glide was used for all docking procedures with a van der Waals (vdw) radius scaling factor of 0.80 and a partial charge cut-off of 0.15 and with no constraints. The XP score was utilized to rank ligands and determine the optimal docked pose for each ligand. Molecular mechanics–generalized Born surface area (MM-GBSA) binding free energy was computed for the top ranked poses using the Prime MM-GBSA module and put in context with the experimental binding affinities. The energy was calculated based on the solvent accessible area in comparison to the energy of individual molecules by calculating the difference in energy of the individual ligand and receptor and the energy of the receptor-ligand complex. Visual evaluation of key binding interactions was also used to finally assess the best active compounds and develop the structure activity relationship. Figures were generated using PyMol 2.0.6 Graphical Software (Schrödinger®, New York, NY, USA).

4. Conclusions

2-Amino-6-methoxypyrimidine derivatives (2–17) were synthesized and characterized successfully. The synthesized derivatives were tested against α-glucosidase and α-amylase enzymes. The derivative 4 exhibited the highest activity against α-glucosidase and α-amylase enzymes with IC50 12.16 ±0.12 µM and IC50 11.13 ± 0.12 µM, respectively. It could be ascribed to the presence of more electronegative fluorine atoms and their suitable interaction with the enzymes. The docking studies were in agreement with the experimental inhibition activity and identified the key structural characteristics of the 2,4-diaminopyrimidine scaffold necessary for the dual inhibition of α-glucosidase and α-amylase.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/molecules30132857/s1.

Author Contributions

S.A., conceptualization, methodology, writing—original draft, writing—review and editing, and supervision; H.A.A., methodology, writing—review and editing; O.A.-S., experimental; M.S.G., methodology, molecular modeling studies, and writing—original draft; M.N., methodology, biological evaluation activity; All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

In silico drug experiments using molecular docking to target α-glucosidase and α-amylase (PDB IDs: 3W37, and 4GQR, respectively) were obtained from the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB). α-glucosidase: https://doi.org/10.2210/pdb3W37/pdb; α-amylase: https://doi.org/10.2210/pdb4GQR/pdb; Other data are contained within the article and Supplementary Materials.

Acknowledgments

We would like to thank the Basic and Applied Scientific Research Centre and Department of Nano-Medicine Research, Institute for Research and Medical Consultations (IRMC) at Imam Abdulrahman Bin Faisal University, for the co-workers and trenching at making the spectral analyses. Thanks to Donya Alsewdan at Research and Development Centre, Saudi Aramco, for the NMR analysis.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Joule, J.; Mills, K. Heterocyclic Chemistry at A Glance, 2nd ed.; John Wiley & Sons: Hoboken, NJ, USA, 2012; ISBN 978-1-118-38019-2. [Google Scholar]
  2. Kumar, S.; Narasimhan, B. Therapeutic Potential of Heterocyclic Pyrimidine Scaffolds. Chem. Cent. J. 2018, 12, 38. [Google Scholar] [CrossRef]
  3. Eicher, T.; Hauptmann, S.; Speicher, A. The Chemistry of Heterocycles: Structures, Reactions, Synthesis, and Applications, 3rd ed.; Wiley-VCH: Hoboken, NJ, USA, 2012; ISBN 978-3-527-32747-8. [Google Scholar]
  4. Becker, S.; Feldmann, J.; Wiedemann, S.; Okamura, H.; Schneider, C.; Iwan, K.; Crisp, A.; Rossa, M.; Amatov, T.; Carell, T. Unified Prebiotically Plausible Synthesis of Pyrimidine and Purine RNA Ribonucleotides. Science 2019, 366, 76–82. [Google Scholar] [CrossRef]
  5. Xu, J.; Tsanakopoulou, M.; Magnani, C.J.; Szabla, R.; Šponer, J.E.; Šponer, J.; Góra, R.W.; Sutherland, J.D. A Prebiotically Plausible Synthesis of Pyrimidine β-Ribonucleosides and Their Phosphate Derivatives Involving Photoanomerization. Nat. Chem. 2017, 9, 303–309. [Google Scholar] [CrossRef] [PubMed]
  6. Kaur, H.; Singh, L.; Chibale, K.; Singh, K. Structure Elaboration of Isoniazid: Synthesis, in Silico Molecular Docking and Antimycobacterial Activity of Isoniazid–Pyrimidine Conjugates. Mol. Divers. 2020, 24, 949–955. [Google Scholar] [CrossRef]
  7. Pan, N.; Liu, C.; Wu, R.; Fei, Q.; Wu, W. Novel Pyrimidine Derivatives Bearing a 1,3,4-Thiadiazole Skeleton: Design, Synthesis, and Antifungal Activity. Front. Chem. 2022, 10, 922813. [Google Scholar] [CrossRef] [PubMed]
  8. Wu, W.; Lan, W.; Wu, C.; Fei, Q. Synthesis and Antifungal Activity of Pyrimidine Derivatives Containing an Amide Moiety. Front. Chem. 2021, 9, 695628. [Google Scholar] [CrossRef]
  9. Tang, X.; Zhan, W.; Chen, S.; Zhou, R.; Hu, D.; Sun, N.; Fei, Q.; Wu, W.; Xue, W. Synthesis, Bioactivity and Preliminary Mechanism of Action of Novel Trifluoromethyl Pyrimidine Derivatives. Arab. J. Chem. 2022, 15, 104110. [Google Scholar] [CrossRef]
  10. Ren, Q.; Liu, X.; Luo, Z.; Li, J.; Wang, C.; Goldmann, S.; Zhang, J.; Zhang, Y. Discovery of Hepatitis B Virus Capsid Assembly Inhibitors Leading to a Heteroaryldihydropyrimidine Based Clinical Candidate (GLS4). Bioorg. Med. Chem. 2017, 25, 1042–1056. [Google Scholar] [CrossRef] [PubMed]
  11. Albratty, M.; Alhazmi, H.A. Novel Pyridine and Pyrimidine Derivatives as Promising Anticancer Agents: A Review. Arab. J. Chem. 2022, 15, 103846. [Google Scholar] [CrossRef]
  12. Gaber, A.A.; Sobhy, M.; Turky, A.; Abdulwahab, H.G.; Al-Karmalawy, A.A.; Elhendawy, M.A.; Radwan, M.M.; Elkaeed, E.B.; Ibrahim, I.M.; Elzahabi, H.S.A.; et al. Discovery of New 1 H-Pyrazolo[3,4-d ]Pyrimidine Derivatives as Anticancer Agents Targeting EGFRWT and EGFRT790M. J. Enzyme Inhib. Med. Chem. 2022, 37, 2283–2303. [Google Scholar] [CrossRef]
  13. Becan, L.; Pyra, A.; Rembiałkowska, N.; Bryndal, I. Synthesis, Structural Characterization and Anticancer Activity of New 5-Trifluoromethyl-2-Thioxo-Thiazolo[4,5-d]Pyrimidine Derivatives. Pharmaceuticals 2022, 15, 92. [Google Scholar] [CrossRef] [PubMed]
  14. Al-Masoudi, W.A.; Al-Masoudi, N.A.; Weibert, B.; Winter, R. Synthesis, X-Ray Structure, in Vitro HIV and Kinesin Eg5 Inhibition Activities of New Arene Ruthenium Complexes of Pyrimidine Analogs. J. Coord. Chem. 2017, 70, 2061–2073. [Google Scholar] [CrossRef]
  15. Al-Masoudi, W.A.; Al-Masoudi, N.A. A Ruthenium Complexes of Monastrol and Its Pyrimidine Analogues: Synthesis and Biological Properties. Phosphorus Sulfur Silicon Relat. Elem. 2019, 194, 1020–1027. [Google Scholar] [CrossRef]
  16. Sharaky, M.; Kamel, M.; Aziz, M.A.; Omran, M.; Rageh, M.M.; Abouzid, K.A.M.; Shouman, S.A. Design, Synthesis and Biological Evaluation of a New Thieno[2,3- d ]Pyrimidine-Based Urea Derivative with Potential Antitumor Activity against Tamoxifen Sensitive and Resistant Breast Cancer Cell Lines. J. Enzyme Inhib. Med. Chem. 2020, 35, 1641–1656. [Google Scholar] [CrossRef]
  17. Liu, L.; Wang, Z.; Gao, C.; Dai, H.; Si, X.; Zhang, Y.; Meng, Y.; Zheng, J.; Ke, Y.; Liu, H.; et al. Design, Synthesis and Antitumor Activity Evaluation of Trifluoromethyl-Substituted Pyrimidine Derivatives. Bioorg. Med. Chem. Lett. 2021, 51, 128268. [Google Scholar] [CrossRef]
  18. Thangarasu, P.; Manikandan, A.; Thamaraiselvi, S. Discovery, Synthesis and Molecular Corroborations of Medicinally Important Novel Pyrazoles; Drug Efficacy Determinations through in Silico, in Vitro and Cytotoxicity Validations. Bioorg. Chem. 2019, 86, 410–419. [Google Scholar] [CrossRef] [PubMed]
  19. Batista, D.; Schwarz, S.; Loesche, A.; Csuk, R.; Costa, P.J.; Oliveira, M.C.; Xavier, N.M. Synthesis of Glucopyranos-6′-Yl Purine and Pyrimidine Isonucleosides as Potential Cholinesterase Inhibitors. Access to Pyrimidine-Linked Pseudodisaccharides through Mitsunobu Reaction. Pure Appl. Chem. 2016, 88, 363–379. [Google Scholar] [CrossRef]
  20. Fatahala, S.S.; Mahgub, S.; Taha, H.; Abd-El Hameed, R.H. Synthesis and Evaluation of Novel Spiro Derivatives for Pyrrolopyrimidines as Anti-Hyperglycemia Promising Compounds. J. Enzyme Inhib. Med. Chem. 2018, 33, 809–817. [Google Scholar] [CrossRef]
  21. Peytam, F.; Adib, M.; Shourgeshty, R.; Firoozpour, L.; Rahmanian-Jazi, M.; Jahani, M.; Moghimi, S.; Divsalar, K.; Faramarzi, M.A.; Mojtabavi, S.; et al. An Efficient and Targeted Synthetic Approach towards New Highly Substituted 6-Amino-Pyrazolo[1,5-a]Pyrimidines with α-Glucosidase Inhibitory Activity. Sci. Rep. 2020, 10, 2595. [Google Scholar] [CrossRef]
  22. Rango, E.; Pastorino, F.; Brignole, C.; Mancini, A.; Poggialini, F.; Di Maria, S.; Zamperini, C.; Iovenitti, G.; Fallacara, A.L.; Sabetta, S.; et al. The Pyrazolo[3,4-d]Pyrimidine Derivative Si306 Encapsulated into Anti-GD2-Immunoliposomes as Therapeutic Treatment of Neuroblastoma. Biomedicines 2022, 10, 659. [Google Scholar] [CrossRef]
  23. Chen, L.; Magliano, D.J.; Zimmet, P.Z. The Worldwide Epidemiology of Type 2 Diabetes Mellitus—Present and Future Perspectives. Nat. Rev. Endocrinol. 2012, 8, 228–236. [Google Scholar] [CrossRef] [PubMed]
  24. Munhoz, A.C.M.; Frode, T.S. Isolated Compounds from Natural Products with Potential Antidiabetic Activity—A Systematic Review. Curr. Diabetes Rev. 2018, 14, 36–106. [Google Scholar] [CrossRef]
  25. Kahn, S.E.; Cooper, M.E.; Del Prato, S. Pathophysiology and Treatment of Type 2 Diabetes: Perspectives on the Past, Present, and Future. Lancet 2014, 383, 1068–1083. [Google Scholar] [CrossRef]
  26. Nawaz, M.; Taha, M.; Qureshi, F.; Ullah, N.; Selvaraj, M.; Shahzad, S.; Chigurupati, S.; Waheed, A.; Almutairi, F.A. Structural Elucidation, Molecular Docking, α-Amylase and α-Glucosidase Inhibition Studies of 5-Amino-Nicotinic Acid Derivatives. BMC Chem. 2020, 14, 43. [Google Scholar] [CrossRef] [PubMed]
  27. Kumar, R.; Mittal, A.; Ramachandran, U. Design and Synthesis of 6-Methyl-2-Oxo-1,2,3,4-Tetrahydro-Pyrimidine-5-Carboxylic Acid Derivatives as PPARγ Activators. Bioorg. Med. Chem. Lett. 2007, 17, 4613–4618. [Google Scholar] [CrossRef]
  28. Bassyouni, F.; Tarek, M.; Salama, A.; Ibrahim, B.; Salah El Dine, S.; Yassin, N.; Hassanein, A.; Moharam, M.; Abdel-Rehim, M. Promising Antidiabetic and Antimicrobial Agents Based on Fused Pyrimidine Derivatives: Molecular Modeling and Biological Evaluation with Histopathological Effect. Molecules 2021, 26, 2370. [Google Scholar] [CrossRef]
  29. Becker, I. Preparation of Pyrimidine Derivatives as Potential Medicinal Agents by the Reaction of 2-Amino-4-Chloro-6-Methylpyrimidine with Primary and Secondary Amines. J. Heterocycl. Chem. 2005, 42, 1289–1295. [Google Scholar] [CrossRef]
  30. Selka, A.; Abidli, A.; Schiavo, L.; Jeanmart, L.; Hanquet, G.; Lubell, W.D. Recent Advances in Sustainable Total Synthesis and Chiral Pool Strategies with Emphasis on (−)-Sclareol in Natural Products Synthesis. Eur. J. Org. Chem 2025, 28, e202400983. [Google Scholar] [CrossRef]
  31. Nawaz, M.; Taha, M.; Qureshi, F.; Ullah, N.; Selvaraj, M.; Shahzad, S.; Chigurupati, S.; Abubshait, S.A.; Ahmad, T.; Chinnam, S.; et al. Synthesis, α-Amylase and α-Glucosidase Inhibition and Molecular Docking Studies of Indazole Derivatives. J. Biomol. Struct. Dyn. 2022, 40, 10730–10740. [Google Scholar] [CrossRef]
  32. Taha, M.; Khan, A.A.; Rahim, F.; Hayat, S.; Imran, S.; Iqbal, N.; Uddin, N.; Khan, K.M.; Anouar, E.H.; Farooq, R.K.; et al. Synthesis, in Vitro Evaluation and Molecular Docking Studies of Hybrid 4-Quinolinyl Bearing 1,3,4-Thiadiazole-2-Amine as a New Inhibitor of α-Amylase and α-Glucosidase. J. Mol. Struct. 2023, 1282, 135173. [Google Scholar] [CrossRef]
  33. Taha, M.; Salahuddin, M.; Almandil, N.B.; Farooq, R.K.; Rahim, F.; Uddin, N.; Nawaz, M.; Alhibshi, A.H.; Anouar, E.H.; Khan, K.M. In Vitro and in Vivo Anti Diabetics Study of New Oxadiazole Derivatives Along with Molecular Docking Study. Polycycl. Aromat. Compd. 2023, 43, 6911–6926. [Google Scholar] [CrossRef]
  34. Mekky, A.E.M.; Taha, N.A.S.; Mohammed, N.G.; Hussein, F.R.M.; Abdelfattah, E.H.; Gamal Eldin, A.A.; Abdelsalam, A.A.M.; Sanad, S.M.H. Development of Pyrazolo[1,5-a]Pyrimidine-Based Antibacterial Agents. Synth. Commun. 2023, 53, 1053–1068. [Google Scholar] [CrossRef]
  35. Elumalai, K.; Shanmugam, A.; Devaraji, M.; Srinivasan, S. Synthesis and Molecular Docking of Pyrimidine Derivatives as Antibacterial Agents. Carbon Resour. Convers. 2024, 7, 100222. [Google Scholar] [CrossRef]
  36. Alamshany, Z.M.; Tashkandi, N.Y.; Othman, I.M.M.; Ishak, E.A.; Gad-Elkareem, M.A.M. Synthesis, Antimicrobial and Antioxidant Activities of Some New Pyrazolo[1,5-a]Pyrimidine and Imidazo[1,2-b]Pyrazole Derivatives Based Isoxazole. Synth. Commun. 2023, 53, 1451–1467. [Google Scholar] [CrossRef]
  37. Teli, G.; Pal, R.; Maji, L.; Purawarga Matada, G.S.; Sengupta, S. Explanatory Review on Pyrimidine/Fused Pyrimidine Derivatives as Anticancer Agents Targeting Src Kinase. J. Biomol. Struct. Dyn. 2023, 42, 1582–1614. [Google Scholar] [CrossRef]
  38. Myriagkou, M.; Papakonstantinou, E.; Deligiannidou, G.-E.; Patsilinakos, A.; Kontogiorgis, C.; Pontiki, E. Novel Pyrimidine Derivatives as Antioxidant and Anticancer Agents: Design, Synthesis and Molecular Modeling Studies. Molecules 2023, 28, 3913. [Google Scholar] [CrossRef]
  39. Al Nasr, I.S.; Corona, A.; Koko, W.S.; Khan, T.A.; Ben Said, R.; Daoud, I.; Rahali, S.; Tramontano, E.; Schobert, R.; Amdouni, N.; et al. Versatile Anti-Infective Properties of Pyrido- and Dihydropyrido[2,3-d]Pyrimidine-Based Compounds. Bioorg. Med. Chem. 2023, 90, 117376. [Google Scholar] [CrossRef] [PubMed]
  40. Manzoor, S.; Almarghalani, D.A.; James, A.W.; Raza, M.K.; Kausar, T.; Nayeem, S.M.; Hoda, N.; Shah, Z.A. Synthesis and Pharmacological Evaluation of Novel Triazole-Pyrimidine Hybrids as Potential Neuroprotective and Anti-Neuroinflammatory Agents. Pharm. Res. 2023, 40, 167–185. [Google Scholar] [CrossRef]
  41. Hassan, A.S.; Morsy, N.M.; Aboulthana, W.M.; Ragab, A. In Vitro Enzymatic Evaluation of Some Pyrazolo[1,5-a]Pyrimidine Derivatives: Design, Synthesis, Antioxidant, Anti-diabetic, anti-Alzheimer, and Anti-arthritic Activities with Molecular Modeling Simulation. Drug Dev. Res. 2023, 84, 3–24. [Google Scholar] [CrossRef]
  42. Amin, S.; Sheikh, K.A.; Iqubal, A.; Ahmed Khan, M.; Shaquiquzzaman, M.; Tasneem, S.; Khanna, S.; Najmi, A.K.; Akhter, M.; Haque, A.; et al. Synthesis, in-Silico Studies and Biological Evaluation of Pyrimidine Based Thiazolidinedione Derivatives as Potential Anti-Diabetic Agent. Bioorg. Chem. 2023, 134, 106449. [Google Scholar] [CrossRef]
  43. Mushtaq, A.; Azam, U.; Mehreen, S.; Naseer, M.M. Synthetic α-Glucosidase Inhibitors as Promising Anti-Diabetic Agents: Recent Developments and Future Challenges. Eur. J. Med. Chem. 2023, 249, 115119. [Google Scholar] [CrossRef] [PubMed]
  44. Finger, V.; Kufa, M.; Soukup, O.; Castagnolo, D.; Roh, J.; Korabecny, J. Pyrimidine Derivatives with Antitubercular Activity. Eur. J. Med. Chem. 2023, 246, 114946. [Google Scholar] [CrossRef]
  45. Sahoo, B.M.; Banik, B.K.; Kumar, B.V.V.R.; Panda, K.C.; Tiwari, A.; Tiwari, V.; Singh, S.; Kumar, M. Microwave Induced Green Synthesis: Sustainable Technology forEfficient Development of Bioactive Pyrimidine Scaffolds. Curr. Med. Chem. 2023, 30, 1029–1059. [Google Scholar] [CrossRef] [PubMed]
  46. Nammalwar, B.; Bunce, R.A. Recent Advances in Pyrimidine-Based Drugs. Pharmaceuticals 2024, 17, 104. [Google Scholar] [CrossRef]
  47. Patil, S.B. Recent Medicinal Approaches of Novel Pyrimidine Analogs: A Review. Heliyon 2023, 9, e16773. [Google Scholar] [CrossRef]
  48. Bhatnagar, A.; Pemawat, G. Functionalized Pyrimidines: Synthetic Approaches and Biological Activities. A Review. Org. Prep. Proced. Int. 2024, 56, 1–18. [Google Scholar] [CrossRef]
  49. Acharya, P.T.; Bhavsar, Z.A.; Jethava, D.J.; Patel, D.B.; Patel, H.D. A Review on Development of Bio-Active Thiosemicarbazide Derivatives: Recent Advances. J. Mol. Struct. 2021, 1226, 129268. [Google Scholar] [CrossRef]
  50. Metwally, M.A.; Bondock, S.; El-Azap, H.; Kandeel, E.E.M. Thiosemicarbazides: Synthesis and Reactions. J. Sulfur Chem. 2011, 32, 489–519. [Google Scholar] [CrossRef]
  51. Kahvecioglu, D.; Ozguven, S.Y.; Sicak, Y.; Tok, F.; Öztürk, M.; Kocyigit-Kaymakcioglu, B. Synthesis and Molecular Docking Analysis of Novel Hydrazone and Thiosemicarbazide Derivatives Incorporating a Pyrimidine Ring: Exploring Neuroprotective Activity. J. Biomol. Struct. Dyn. 2024, 1–15. [Google Scholar] [CrossRef]
  52. Şenkardeş, S.; Bolat, İ.; Şahinbey, H.; Karakuş, S.; Erdoğan, Ö.; Cantürk, P.; Özgüven, S.Y.; Çevik, Ö. Design, Synthesis and Molecular Modeling Studies of Thiosemicarbazide & Thiazolyl-Hydrazone Derivatives as Potential Anticancer Agents and Topoisomerase Inhibitors. J. Mol. Struct. 2024, 1302, 137488. [Google Scholar] [CrossRef]
  53. Sherje, A.P.; Kulkarni, V.; Murahari, M.; Nayak, U.Y.; Bhat, P.; Suvarna, V.; Dravyakar, B. Inclusion Complexation of Etodolac with Hydroxypropyl-Beta-Cyclodextrin and Auxiliary Agents: Formulation Characterization and Molecular Modeling Studies. Mol. Pharm. 2017, 14, 1231–1242. [Google Scholar] [CrossRef] [PubMed]
  54. Burley, S.K.; Bhikadiya, C.; Bi, C.; Bittrich, S.; Chen, L.; Crichlow, G.V.; Christie, C.H.; Dalenberg, K.; Di Costanzo, L.; Duarte, J.M.; et al. RCSB Protein Data Bank: Powerful New Tools for Exploring 3D Structures of Biological Macromolecules for Basic and Applied Research and Education in Fundamental Biology, Biomedicine, Biotechnology, Bioengineering and Energy Sciences. Nucleic Acids Res. 2021, 49, D437–D451. [Google Scholar] [CrossRef] [PubMed]
  55. Lu, C.; Wu, C.; Ghoreishi, D.; Chen, W.; Wang, L.; Damm, W.; Ross, G.A.; Dahlgren, M.K.; Russell, E.; Von Bargen, C.D.; et al. OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical Space. J. Chem. Theory Comput. 2021, 17, 4291–4300. [Google Scholar] [CrossRef] [PubMed]
  56. Alves, M.; Froufe, H.; Costa, A.; Santos, A.; Oliveira, L.; Osório, S.; Abreu, R.; Pintado, M.; Ferreira, I. Docking Studies in Target Proteins Involved in Antibacterial Action Mechanisms: Extending the Knowledge on Standard Antibiotics to Antimicrobial Mushroom Compounds. Molecules 2014, 19, 1672–1684. [Google Scholar] [CrossRef]
  57. Kwofie, S.K.; Dankwa, B.; Odame, E.A.; Agamah, F.E.; Doe, L.P.A.; Teye, J.; Agyapong, O.; Miller, W.A.; Mosi, L.; Wilson, M.D. In Silico Screening of Isocitrate Lyase for Novel Anti-Buruli Ulcer Natural Products Originating from Africa. Molecules 2018, 23, 1550. [Google Scholar] [CrossRef]
  58. Jaundoo, R.; Bohmann, J.; Gutierrez, G.E.; Klimas, N.; Broderick, G.; Craddock, T.J.A. Using a Consensus Docking Approach to Predict Adverse Drug Reactions in Combination Drug Therapies for Gulf War Illness. Int. J. Mol. Sci. 2018, 19, 3355. [Google Scholar] [CrossRef]
Molecules 30 02857 sch001
Scheme 1. Preparation method of 2-amino-6-methoxypyrimidine derivatives (2–17).
Scheme 1. Preparation method of 2-amino-6-methoxypyrimidine derivatives (2–17).
Molecules 30 02857 sch001
Molecules 30 02857 g001
Figure 1. Binding poses of compounds 4 (green), 6 (brown), 9 (blue), 11 (yellow), 14 (pink), 16 (magenta), and 17 (red) in (a) α-glucosidase (PDB code: 3W37) and (b) α-amylase (PDB code: 4GQR) active sites.
Figure 1. Binding poses of compounds 4 (green), 6 (brown), 9 (blue), 11 (yellow), 14 (pink), 16 (magenta), and 17 (red) in (a) α-glucosidase (PDB code: 3W37) and (b) α-amylase (PDB code: 4GQR) active sites.
Molecules 30 02857 g001
Molecules 30 02857 g002
Figure 2. (a) Three-dimensional representation of the binding interactions between compound 4 and α-glucosidase (PDB code: 3W37) active site and the interacting residues were shown as cartoon, sticks (carbon atoms colored in magenta), and sticks (carbon atom colored in green), respectively. Potential electrostatic interactions are represented as yellow dotted lines and are measured in Angstrom. (b) Two-dimensional ligand–protein binding interactions between compound 4 and α-glucosidase (PDB code: 3W37) active site.
Figure 2. (a) Three-dimensional representation of the binding interactions between compound 4 and α-glucosidase (PDB code: 3W37) active site and the interacting residues were shown as cartoon, sticks (carbon atoms colored in magenta), and sticks (carbon atom colored in green), respectively. Potential electrostatic interactions are represented as yellow dotted lines and are measured in Angstrom. (b) Two-dimensional ligand–protein binding interactions between compound 4 and α-glucosidase (PDB code: 3W37) active site.
Molecules 30 02857 g002
Molecules 30 02857 g003
Figure 3. (a) Three-dimensional representation of the binding interactions between compound 4 and α-amylase (PDB code: 4GQR) active site and the interacting residues, which are shown as cartoon, sticks (carbon atoms colored in magenta), and sticks (carbon atom colored in green), respectively. Potential electrostatic interactions are represented as yellow dotted lines and are measured in Angstrom. (b) Two-dimensional ligand–protein binding interactions between compound 4 and α-amylase (PDB code: 4GQR) active site.
Figure 3. (a) Three-dimensional representation of the binding interactions between compound 4 and α-amylase (PDB code: 4GQR) active site and the interacting residues, which are shown as cartoon, sticks (carbon atoms colored in magenta), and sticks (carbon atom colored in green), respectively. Potential electrostatic interactions are represented as yellow dotted lines and are measured in Angstrom. (b) Two-dimensional ligand–protein binding interactions between compound 4 and α-amylase (PDB code: 4GQR) active site.
Molecules 30 02857 g003
Molecules 30 02857 g004
Figure 4. 3D binding interactions of compound 17 with (a) α-glucosidase (PDB: 3W37) and (b) α-amylase (PDB: 4GQR). Interacting residues are shown as cartoon and sticks (C atoms in magenta and green). Electrostatic interactions are indicated by yellow dashed lines (in Å).
Figure 4. 3D binding interactions of compound 17 with (a) α-glucosidase (PDB: 3W37) and (b) α-amylase (PDB: 4GQR). Interacting residues are shown as cartoon and sticks (C atoms in magenta and green). Electrostatic interactions are indicated by yellow dashed lines (in Å).
Molecules 30 02857 g004
Table 1. The biological activities of the pyrimidine derivatives against α-glucosidase and α-amylase (IC50 “μM” ± SD, n = 5) for selected compounds.
Table 1. The biological activities of the pyrimidine derivatives against α-glucosidase and α-amylase (IC50 “μM” ± SD, n = 5) for selected compounds.
Molecules 30 02857 i001
Comp. NoRα-Glucosidase (IC50, µM)α-Amylase (IC50, µM)
43-F12.16 ± 0.1211.13 ± 0.12
63-Cl16.13 ± 0.1115.17 ± 0.07
93-Br19.11 ± 0.1118.16 ± 0.08
113-NO222.11 ± 0.1321.14 ± 0.12
143-OCH330.12 ± 0.1333.18 ± 0.14
164-CH336.14 ± 0.1234.24 ± 0.16
173-CN42.19 ± 0.1340.16 ± 0.11
Acarbose 10.60 ± 0.1711.30 ± 0.12
Table 2. Experimental IC50, XP score, and computational binding energy of the pyrimidine derivatives and the reference inhibitor, acarbose, with α-glucosidase and α-amylase.
Table 2. Experimental IC50, XP score, and computational binding energy of the pyrimidine derivatives and the reference inhibitor, acarbose, with α-glucosidase and α-amylase.
Comp. Noα-Glucosidaseα-Amylase
(IC50, µM)XP ScoreMM-GBSA
dG Bind		(IC50, µM)XP ScoreMM-GBSA
dG Bind
412.16 ± 0.12−4.15.311.13 ± 0.12−4.5−0.4
616.13 ± 0.11−5.013.615.17 ± 0.07−4.7−8.8
919.11 ± 0.11−4.812.718.16 ± 0.08−5.00.4
1122.11 ± 0.13−3.929.221.14 ± 0.12−4.8−4.1
1430.12 ± 0.13−2.917.333.18 ± 0.14−5.211.5
1636.14 ± 0.12−4.8−2.734.24 ± 0.16−4.3−6.5
1742.19 ± 0.13−2.416.040.16 ± 0.11−4.3−2.7
Acarbose10.60 ± 0.17−11.5−29.911.30 ± 0.12−10.0−34.7
Table 3. Relative mean standard deviation (RMSD) values of the binding poses of compounds 4, 6, 9, 11, 14, 16, and 17 in reference to compound 4.
Table 3. Relative mean standard deviation (RMSD) values of the binding poses of compounds 4, 6, 9, 11, 14, 16, and 17 in reference to compound 4.
Comp. Noα-Glucosidaseα-Amylase
(IC50, µM)RMSD(IC50, µM)RMSD
412.16 ± 0.120.011.13 ± 0.120.0
616.13 ± 0.110.0715.17 ± 0.070.6
919.11 ± 0.111.518.16 ± 0.081.7
1122.11 ± 0.131.721.14 ± 0.121.7
1430.12 ± 0.132.333.18 ± 0.141.8
1636.14 ± 0.121.234.24 ± 0.161.2
1742.19 ± 0.138.640.16 ± 0.116.3
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Al-Shehri, O.; Abubshait, S.; Nawaz, M.; Gomaa, M.S.; Abubshait, H.A. One-Pot Synthesis of Novel Pyrimidine Derivatives with Potential Antidiabetic Activity Through Dual α-Glucosidase and α-Amylase Inhibitors. Molecules 2025, 30, 2857. https://doi.org/10.3390/molecules30132857

AMA Style

Al-Shehri O, Abubshait S, Nawaz M, Gomaa MS, Abubshait HA. One-Pot Synthesis of Novel Pyrimidine Derivatives with Potential Antidiabetic Activity Through Dual α-Glucosidase and α-Amylase Inhibitors. Molecules. 2025; 30(13):2857. https://doi.org/10.3390/molecules30132857

Chicago/Turabian Style

Al-Shehri, Ohood, Samar Abubshait, Muhammad Nawaz, Mohamed S. Gomaa, and Haya A. Abubshait. 2025. "One-Pot Synthesis of Novel Pyrimidine Derivatives with Potential Antidiabetic Activity Through Dual α-Glucosidase and α-Amylase Inhibitors" Molecules 30, no. 13: 2857. https://doi.org/10.3390/molecules30132857

APA Style

Al-Shehri, O., Abubshait, S., Nawaz, M., Gomaa, M. S., & Abubshait, H. A. (2025). One-Pot Synthesis of Novel Pyrimidine Derivatives with Potential Antidiabetic Activity Through Dual α-Glucosidase and α-Amylase Inhibitors. Molecules, 30(13), 2857. https://doi.org/10.3390/molecules30132857

Article Metrics

Back to TopTop